NCT01520831View on ClinicalTrials.gov

Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 30, 1999

Primary Completion Date

May 31, 2000

Study Completion Date

May 31, 2000

Conditions
DiabetesHealthy
Interventions
DRUG

biphasic insulin aspart 30

One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days

DRUG

biphasic insulin aspart 50

One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days

DRUG

biphasic insulin aspart 70

One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days

DRUG

insulin aspart

One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01520831 - Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects | Biotech Hunter | Biotech Hunter